We are live on ! Find out more
LBPH

Longboard Pharmaceuticals, Inc. Common Stock

Delisted

LBPH was delisted on the 29th of November, 2024.

17 hedge funds and large institutions have $71.7M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% less funds holding

Funds holding: 2217 (-5)

50% less capital invested

Capital invested by funds: $143M → $71.7M (-$71.1M)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
17
Holders Change
-5
Holders Change %
-22.73%
% of All Funds
0.3%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
3
Reduced
6
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$20.9M -$345K -34,597 -1%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$20.1M -$154K -15,460 -0.7%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$18.6M +$445K +44,695 +2%
FCM
4
Farallon Capital Management
California
$7.39M
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.51M +$1.1M +110,545 +201%
O
6
OrbiMed
New York
$1.03M -$1.86M -186,500 -62%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$778K -$395K -39,640 -32%
Millennium Management
8
Millennium Management
New York
$497K -$1.35M -135,906 -71%
IHAM
9
Integral Health Asset Management
New York
$274K
LCM
10
Laurion Capital Management
New York
$191K -$34.7K -3,482 -14%
BlackRock
11
BlackRock
New York
$164K +$179K +17,999 New
TD Asset Management
12
TD Asset Management
Ontario, Canada
$153K
Renaissance Technologies
13
Renaissance Technologies
New York
$95K +$104K +10,400 New
UBS Group
14
UBS Group
Switzerland
$29K +$25.8K +2,593 +435%
ASN
15
Advisory Services Network
Georgia
$9K +$9.96K +1,000 New
Citigroup
16
Citigroup
New York
-$6.62M -405,645 Closed
Citadel Advisors
17
Citadel Advisors
Florida
-$2.96M -181,473 Closed
DKCM
18
Davidson Kempner Capital Management
New York
-$405K -25,000 Closed
Goldman Sachs
19
Goldman Sachs
New York
-$410K -25,000 Closed
ECM
20
Endurant Capital Management
California
-$267K -16,327 Closed
ECM
21
ExodusPoint Capital Management
New York
-$246K -15,011 Closed
Wellington Management Group
22
Wellington Management Group
Massachusetts
-$185K -11,333 Closed
Jane Street
23
Jane Street
New York
-$174K -10,606 Closed
MS
24
Maven Securities
Jersey
-$128K -7,813 Closed
Bank of America
25
Bank of America
North Carolina
-$7K -404 Closed

LBPH Hedge Fund Activity: Q2 2021 in Review

17 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q2 2021, worth a combined $71.7M — down 50% from $143M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of LBPH and 5 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $1.1M. The largest seller was Citigroup, exiting entirely with an estimated $6.62M sold.

  • 17 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q2 2021, down from 22 in Q1 2021.
  • Funds reported $71.7M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 50% quarter-over-quarter.
  • 5 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 10 closed out, a net change of -5 holders.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $1.1M added.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Citigroup, an estimated $6.62M sold.

Based on aggregated 13F filings for Q2 2021.